ResourcesHeadlineDark Gray3.00000000000000Resources
Arizona's Biomedical HubHTML ContentNavy1.00000000000000Arizona's Biomedical Hub<div class="ExternalClass51D6FFB5BED8403D9B702D5D61945ACA"><html> <div class="ExternalClass5F504BE0FE1A46E7A6C274CE3EB32A85"> <span style="font-size:17.3333px;">As the 5th largest city in the nation, Phoenix boasts institutes of excellence in precision medicine, genomics, molecular medicine, cancer research, healthcare analytics, medical education, and others. Nowhere is this more concentrated than on the Phoenix Biomedical Campus, 30-acres at the center of Phoenix’s innovator’s core, the PHX Core, in Downtown Phoenix. </span></div><div class="ExternalClass5F504BE0FE1A46E7A6C274CE3EB32A85"><span style="font-size:17.3333px;"><br>Join the frontier of personalized medicine in Phoenix. Unprecedented collaboration between innovators and institutions of excellence sets a new standard. This is the city in which ideas are nurtured, innovation is celebr​ated, and n​ew explorers are welcome.  </span></div><div class="ExternalClass5F504BE0FE1A46E7A6C274CE3EB32A85"><p><span style="font-size:17.3333px;">​</span></p><p style="text-align:center;"><span style="font-size:17.3333px;">​<a href="/Documents/Phoenix%20Biomedical%20Campus%202020.pdf" target="_blank"><span style="background-color:rgb(242, 242, 242);">Phoenix Biomedical Campus Brochure Download</span></a><span style="background-color:rgb(242, 242, 242);">​</span></span></p></div></html></div>1
Explore the PossibilitiesVideoLight Gray2.00000000000000Explore the Possibilities<div class="ExternalClass026728C8E0B94CC0AFE4893D42958BAC"><html> <p> <span id="ms-rterangepaste-start" aria-hidden="true"></span><span id="ms-rterangepaste-start"></span><a target="_blank" href="https://www.youtube.com/watch?v=i5a6yYRY1zc">https://www.youtube.com/watch?v=i5a6yYRY1zc</a>​<span id="ms-rterangepaste-end"></span></p> </html></div>

 

 

About the City of PhoenixAbout the City of Phoenix1.00000000000000https://www.phoenix.gov/econdevPencilIcons
Let the City of Phoenix Assist YouLet the City of Phoenix Assist You2.00000000000000https://www.phoenix.gov/econdev/bioHandIcons
Workforce AvailabilityWorkforce Availability3.00000000000000http://www.arizonaatwork.com/phoenix/Bar GraphIcons

 

 

Arming the rabbit pox virus to fight cancerArming the rabbit pox virus to fight cancer<div class="ExternalClass2D5A152ABD844A598AAEEF1473D7917F"><html> <span style="font-size:17.3333px;">​Oncolytic viruses hold promise as cancer treatments due to their cancer-killing prowess and ability to be combined with other therapies. But few drugs derived from oncolytic viruses have made it to the market.</span><br style="font-size:17.3333px;"><br style="font-size:17.3333px;"><span style="font-size:17.3333px;">Arizona State University spinout OncoMyx Therapeutics is designing anti-cancer therapies from a type of rabbit pox virus called myxoma. The company has early data showing that the virus, when armed with relevant transgenes, can suppress different types of cancer in mice both as an injection directly into tumors and through systemic administration by intravenous infusion.</span><br style="font-size:17.3333px;"><br style="font-size:17.3333px;"><span style="font-size:17.3333px;">In mouse models of melanoma and bone cancer, the drug significantly slowed tumor growth, and it was even better at shrinking tumors and prolonging the animal’s lives when paired with a PD-1 or PD-L1 inhibitor, according to data presented at the Society for Immunotherapy of Cancer (SITC) virtual meeting.</span>​<br><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;"></span><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;" id="ms-rterangepaste-start"></span><span style="font-size:17.3333px;"> </span><p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;"><br></span></p><p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">“These data support the further development of our multi-armed myxoma virotherapies in combination with checkpoint inhibitors and other immuno-oncology approaches to increase the number of cancer patients who could benefit from immunotherapies,” Steve Potts, Ph.D., co-founder and CEO of OncoMyx, </span><a target="_blank" href="https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/" rel="nofollow" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">said</span></a><span style="font-size:17.3333px;"> in a statement.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Myxoma virus, like many other oncolytic viruses, works by directly infecting cancer cells, causing them to die. This process also releases tumor antigens that can stimulate an immune response to the cancer. But myxoma virus can offer several advantages.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">First, the natural host of myxoma virus are rabbits, and it doesn’t cause disease in any other animals or in humans. This means that the virus can be systemically injected into people safely, and that it doesn’t have to overcome pre-existing immunity, which might otherwise kill it off before it could provide any therapeutic benefit.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">What’s more, as a large DNA virus, myxoma virus can serve as a vector to carry additional genes to target different facets of cancer immunity.</span></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">OncoMyx researchers showed that myxoma virus can replicate with up to six genes transferred to it, and that the virus can effectively express transgenes. These multi-armed myxoma viruses inhibited cancer growth across a wide range of human tumor types in lab dishes as well as in mice bearing human tumor xenografts.<br style=""></span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">The team further tested myxoma viruses bearing up to three genes, or arms, in immunocompetent mice. One arm was a cytokine that modulates T cell and natural-killer cell activity and recruitment to the tumor, Leslie Sharp, chief scientific officer of OncoMyx, explained in an email to FierceBiotechResearch. A second arm remodels the tumor microenvironment and removes cancer cells' suppression of T-cell immunity. And the third arm is a proinflammatory agent.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Unedited viruses were able to slow the growth of some tumors, but the effects were clearly better when the genes were edited in. “As is typical for preclinical models, response varies by model, but generally gives dose-dependent changes in tumor growth inhibition in the range of 70% to 99% including tumor regression and complete responses,” Sharp said. Tumor suppression was observed following both intratumoral and intravenous delivery of the viruses, and it led to increased survival of the animals.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Moreover, myxoma virus generally did better when being paired with either a PD-1 or PD-L1 inhibiting drug. That was even the case in a melanoma model that’s known to be resistant to immune checkpoint inhibition, suggesting it could be used in combination therapy to further boost the anti-tumor response.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Further analysis showed that multi-armed myxoma increased the population of tumor-infiltrating immune cells; the ratio of CD8+ T cells and immune-suppressing regulatory T cells was higher, and so was the ratio between pro-inflammatory M1 macrophages and healing-supportive M2 macrophages.​<br style=""></span></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Very few virus-based cancer treatments have made it to market, and the ones that did have their limitations.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Amgen’s FDA-approved melanoma therapy Imlygic, for example, uses a cancer-killing herpes virus, which is genetically edited to reduce its harm on noncancerous tissue. But it can’t completely prevent it from infecting healthy cells. Plus, it needs to be injected directly into melanoma tumors to achieve the best results and avoid toxicity. Oncorine, the world’s first commercial oncolytic virus product, approved in China in 2005 for the treatment of head and neck cancer, is based on an adenovirus that also goes through an attenuation step to limit its damage of healthy cells. Because both types of viruses can infect humans, therapies based on them must overcome pre-existing immunity.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Nevertheless, oncolytic viruses remain hot targets of cancer research. A team at City of Hope recently </span><a target="_blank" href="https://www.fiercebiotech.com/research/virus-combo-makes-solid-tumors-vulnerable-to-car-t-attack-mice" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">engineered</span></a><span style="font-size:17.3333px;"> an oncolytic virus to express the CD19 protein on solid tumor cells, thereby allowing them to be targetable by CD19-directed CAR-T cell therapies, which so far have only worked in some blood cancers.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">Researchers led by Astellas’ drug discovery unit </span><a target="_blank" href="https://www.fiercebiotech.com/research/cancer-killing-virus-boosts-immuno-oncology-responses-mice-astellas-led-study" style="box-sizing:inherit;color:rgb(237, 28, 38);font-weight:bold;"><span style="font-size:17.3333px;">used</span></a><span style="font-size:17.3333px;"> a vaccinia virus, another large DNA virus that also belongs to the poxvirus family, to carry two cytokines—IL-7 and IL-12—to stimulate an anti-cancer immune response. The therapy also appeared to work in synergy with anti-PD-1 or anti-CTLA-4 antibodies.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">With promising animal data, OncoMyx is now working on programs to enable a first-in-human clinical trial for its lead program, dubbed OM101. “We can focus on large unmet needs in major cancer areas, for example, lung, gastro-intestinal, gynecologic, etc., and then look at patients within these populations where the mechanisms of interest are driving their tumor growth and will be most likely to benefit from therapy,” Potts said.</span></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"></p> <p class="MsoNormal" style="box-sizing:inherit;color:rgb(51, 51, 51);font-family:overpass, sans-serif;"><span style="font-size:17.3333px;">The company raised a $25 million series A funding round in 2019, led by Boehringer Ingelheim Venture Fund, Delos Capital and Xeraya Capital.​<br style=""></span></p><span style="font-size:17.3333px;"> </span><span style="font-size:17.3333px;" id="ms-rterangepaste-end"></span><span style="font-size:17.3333px;"> </span><p> <br> </p> </html></div>
Listen to Phoenix Leaders Share Insights about the Rising Bioindustry in the Nation’s 5th Largest City Listen to Phoenix Leaders Share Insights about the Rising Bioindustry in the Nation’s 5th Largest City <div class="ExternalClass85477EA12D3E483194E93A2800419195"><html> Listen to conversations with Phoenix Mayor Kate Gallego and other leaders as they share their insights with Tom Osha, Senior Vice President of Innovation and Economic Development at Wexford Science+Technology, about Phoenix’s growing and thriving bioindustry ecosystem.<br><br>Listen to these conversations beginning June 8, 2020 <a target="_blank" href="https://wexfordscitech.com/thecommons/"><strong><em>here</em></strong></a>:<br><ul><li><strong>Episode 1 –</strong> <em>The Role of Innovation Districts in Restarting the Economy</em><br></li><li><strong>Episode 2 </strong>– <em>Arizona’s Life Sciences Roadmap</em><br></li><li><strong>Episode 3 </strong>– <em>Phoenix is HOT! And so is the Phoenix Biomedical Campus</em></li><li><strong>Episode 4 </strong>– <em>ASU #1 for Innovation</em></li><li><strong>Episode </strong><strong>5 </strong>– <em>A Fertile Environment for Start-Ups: The OncoMyx Story</em></li><li><strong>Episode </strong><strong>6 </strong>– <em>Building the Life Sciences Workforce</em></li><li><strong>Episode </strong><strong>7 </strong>– <em>The Wexford Knowledge Community</em></li></ul>Sparking collaboration is the purpose of the Phoenix bioindustry ecosystem. Phoenix, Arizona, where each day is a relentless pursuit of cures. From discovery to delivery, join Phoenix companies and the leading edge of personalized medicine. Come to a young, vibrant community in an environment where ideas thrive. With a lack of barriers to enter the market, America’s fastest-growing population, and an entrepreneurial pioneer spirit, this is the place for rising to success. Join Translational Genomics Research Institute, three research universities, and world class bioscientists on the Phoenix Biomedical Campus. Located in dynamic Downtown Phoenix, home to Wexford Science and Technology’s collaboration-designed bioscience research building, the Center for Entrepreneurial Innovation, and unlimited opportunities. Learn more at <a target="_blank" href="/"><strong>www.biomedicalphoenix.com</strong></a> and <a target="_blank" href="https://www.phoenix.gov/econdev/bio"><strong>www.phoenix.gov/econdev/bio</strong> </a> <p> <br> </p> </html></div>
Event: Open Invitation for Tours – 850 N 5th Street Innovation Center by Wexford Science + TechnologyEvent: Open Invitation for Tours – 850 N 5th Street Innovation Center by Wexford Science + Technology<div class="ExternalClassD6A5839987B146ED8E93B707FCD8FB47"><html> <p>​<br></p><p>After years of visioning, planning, and construction, 850 N 5th Street is available for tours. The building is a collaborative effort between the City of Phoenix, Arizona State University, and Wexford Science & Technology, LLC. Totaling 227,000 SF with 100,000 SF of commercial lab or office space on the top three floors above Arizona State University research and innovation and GateWay Community College's Center for Entrepreneurial Innovation. 850 N 5th Street will be a gathering hub for life science and biomedical innovation. The building is part of ongoing expansion on the Phoenix Biomedical Campus, connecting the downtown biomedical campus to the Roosevelt Row Arts District. Designed to integrate research, entrepreneurial activity, and corporate engagement, 850 N 5th Street serves as a bridge between the surrounding neighborhoods, the academic community, and the professional community. The building's design purposefully invites the neighborhood to participate in its success through the first-floor program elements that are visually porous and accessible. A portion of the building will include turn-key lab space for private research, growing companies, or a soft-landing option for larger companies locating in Phoenix.</p><p> </p><p>To schedule a tour or receive information about available lease space please contact Kyle Jardine at <a target="_blank" href="mailto:%20Kyle.Jardine@wexfordscitech.com"><strong>Kyle.Jardine@wexfordscitech.com​</strong></a>  480.779.7181<br></p><p> <br> </p> </html></div>

© City of Phoenix Community and Economic Development